source
- Regeneron Ventures leads $75 million Series A for eczema-focused antibody startup InfinimmuneInfinimmune, a Bay Area biotech developing antibody therapies for eczema, announced a $75 million Series A financing round. The round was co-led by Regeneron Ventures and Playground Global, with p…
- Latigo and BlossomHill file Nasdaq IPO plans to fund pain and cancer pipelinesLatigo Biotherapeutics and BlossomHill Therapeutics, both based in California, have filed applications to list on the Nasdaq Global Select Market. Latigo aims to raise up to $285.2 million to advan…